Thomas Vescio
Horizon Therapeutics (United States)(US)
Publications by Year
Research Areas
Antimicrobial Resistance in Staphylococcus, Bacterial Identification and Susceptibility Testing, Ophthalmology and Eye Disorders, Bacterial biofilms and quorum sensing, Metabolism and Genetic Disorders
Most-Cited Works
- → Teprotumumab for the Treatment of Active Thyroid Eye Disease(2020)672 cited
- → Management of Outbreaks of Methicillin-ResistantStaphylococcus aureusInfection in the Neonatal Intensive Care Unit: A Consensus Statement(2006)121 cited
- → Microbiologic Surveillance Using Nasal Cultures Alone Is Sufficient for Detection of Methicillin-Resistant Staphylococcus aureus Isolates in Neonates(2003)47 cited
- → Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia(2006)28 cited
- → Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients(2019)18 cited
- → Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders(2020)15 cited
- Teprotumumab use in a real-world setting: Expanded access program findings(2021)
- → The Role of Molecular Typing in the Epidemiologic Investigation and Control of Nosocomial Infections(2003)1 cited